RAPT Therapeutics, Inc.RAPTEarnings & Financial Report
Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.
Revenue
$0
Gross Profit
N/A
Operating Profit
$-21.7M
Net Profit
$-21.2M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-0.63
RAPT Therapeutics, Inc. Q3 FY2022 Financial Summary
RAPT Therapeutics, Inc. reported revenue of $0 for Q3 FY2022, with a net profit of $-21.2M (down 13.9% YoY) (N/A margin).
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-21.2M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q3 FY2022 |
RAPT Therapeutics, Inc. Annual Revenue by Year
RAPT Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2022 revenue was $1.5M).
| Year | Annual Revenue |
|---|---|
| 2022 | $1.5M |
RAPT Therapeutics, Inc. Quarterly Revenue & Net Profit History
RAPT Therapeutics, Inc. results over the last 6 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2023 | $0 | — | $-31.4M | N/A |
| Q2 FY2023 | $0 | — | $-25.3M | N/A |
| Q4 FY2022 | $0 | — | $-23.0M | N/A |
| Q3 FY2022 | $0 | — | $-21.2M | N/A |
| Q2 FY2022 | $886.0K | +2.0% | $-19.2M | -2165.2% |
| Q1 FY2022 | $641.0K | -47.5% | $-20.5M | -3193.1% |
Income Statement
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|
| Revenue | $641000 | $886000 | $0 | $0 | $0 | $0 |
| YoY Growth | -47.5% | 2.0% | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|
| Assets | $187.5M | $222.0M | $209.5M | $266.2M | $220.8M | $199.7M |
| Liabilities | $19.7M | $19.9M | $20.2M | $21.0M | $21.1M | $26.9M |
| Equity | $167.8M | $202.1M | $189.3M | $245.2M | $199.7M | $172.8M |
Cash Flow
| Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q2 2023 | Q3 2023 | |
|---|---|---|---|---|---|---|
| Operating CF | $-15.6M | $-15.2M | $-17.1M | $-22.8M | $-28.8M | $-21.9M |